If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
VIDEO: Reyvow® (lasmiditan): CENTURION Study Clinical Trial Design
CENTURION was a phase 3 double-blind, placebo-controlled study that evaluated the first attack efficacy, consistency of response, and safety of Reyvow (lasmiditan) in the acute treatment of 4 migraine attacks with or without aura.
Date of Last Review: September 22, 2021
Document Number: VV-MED-113985